Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.

被引：0
|
作者：
Fountzilas, Christos
Rosario, Spencer
Withers, Henry G.
Mukherjee, Sarbajit
Bajor, David L.
Saltzman, Joel N.
Wang, Chong
Attwood, Kristopher
Knudsen, Erik S.
Witkiewicz, Agnieszka K.
Iyer, Renuka V.
Boland, Patrick M.
机构：
[1] Roswell Pk Comprehens Canc Ctr, Div GI Med, Dept Med, Buffalo, NY USA
[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[3] Case Western Reserve Univ, Case Comprehens Canc Ctr, Univ Hosp, Seidman Canc Ctr, Cleveland, OH USA
[4] Cleveland Clin, Cleveland, OH USA
[5] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
178
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [41] Predicting overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT): The British Columbia Cancer Agency (BCCA) mCRC score
    Chen, Leo
    Gresham, Gillian
    Cheung, Winson Y.
    Kennecke, Hagen F.
    Renouf, Daniel John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy
    Angus, L.
    van Helden, E. J.
    van Es, S. C.
    Boon, E.
    van Herpen, C. M. L.
    de Groot, D. J.
    de Vries, E. G. E.
    van Oordt, C. W. Menke-van der Houven
    Sleijfer, S.
    Verheul, H. M.
    Jansen, M. P. H. M.
    ANNALS OF ONCOLOGY, 2018, 29 : 50 - 50
  • [43] Association of FcγRIIa and FcγRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan
    Bibeau, F.
    Crapez, E.
    Di Fiore, F.
    Thezenas, S.
    Sabourin, J.
    Lamy, A.
    Frebourg, T.
    Michel, P.
    Ychou, M.
    Boissiere-Michot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study
    Mathias, C. de Cerqueira
    Perazzo, F.
    Simon, S.
    Fein, L.
    Hidalgo, J.
    Murad, A. M.
    Lerzo, G.
    Esser, R.
    Scheid, S.
    Buzaid, A. C.
    EJC SUPPLEMENTS, 2007, 5 (04): : 252 - 253
  • [45] Cetuximab plus bevacizumab in patients (pts) with metastatic colorectal cancer (mCRC) who have failed on irinotecan, oxaliplatin and fluoropyrimidines-based chemotherapy
    Souglakos, J.
    Kalbakis, K.
    Vamvakas, N.
    Kalykaki, A.
    Kotsakis, A.
    Agelaki, S.
    Karampeazis, A.
    Gioulbasanis, J.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [47] Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial
    Folprecht, G.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Zubel, A.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISNÚ Program
    Sastre, J.
    de la Orden, V.
    Martinez, A.
    Bando, I.
    Santamaria, I.
    Bellosillo Paricio, B.
    Palanca, S.
    Peligros, I.
    Mediero, B.
    Llovet, P.
    Moreno, V.
    Vieitez, J. M.
    Garcia-Alfonso, P.
    Gil, S.
    Ortiz Morales, M. J.
    Salud Salvia, M. A.
    Quintero, G.
    Gesto, F. A.
    Aranda Aguilar, E.
    Diaz Rubio, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] BASELINE LEVELS OF CIRCULATING ANGIOGENIC FACTORS IN METASTATIC COLORECTAL CANCER PTS (MCRC) TREATED WITH BEVACIZUMAB (BEV)
    Martinetti, A.
    Bajetta, E.
    Dibartolomeo, M.
    Dotti, K. F.
    Bianchi, F.
    Sottotetti, E.
    Gevorgyan, A.
    Celio, L.
    Fossile, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 66 - 66
  • [50] Outcomes of elderly chemorefractory metastatic colorectal (mCRC) patients (pts) treated with regorafenib: a single institution experience
    Cardone, C.
    Sforza, V.
    Nappi, A.
    Capasso, A.
    Ferrara, M. L.
    Martini, G.
    Napolitano, S.
    Vitiello, P.
    Vitale, P.
    Zanaletti, N.
    Diadema, M.
    Orditura, M.
    De Vita, F.
    Troiani, T.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2016, 27
12345